Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has provided an announcement.
MindBio Therapeutics has begun targeting the global digital health diagnostics market with its AI-powered speech analytics platform, which uses voice as a biomarker to detect and even estimate levels of alcohol and hallucinogenic drug intoxication. By showcasing its technology in the U.S. and developing an enterprise-grade platform for sectors such as mining, aviation, construction, call centres, mental health and law enforcement, the company is positioning itself as a first mover in scalable, non-invasive workplace and health monitoring solutions that could lower testing costs and address regulatory demands in high-risk industries.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a Vancouver-based biotechnology company specializing in clinical drug and alcohol research and AI-driven health prediction technologies. Leveraging speech analytics and machine learning, it has developed voice-based diagnostic tools for detecting drug and alcohol intoxication, targeting consumer and enterprise applications across workplaces, law enforcement, mental health, and telehealth markets.
Average Trading Volume: 7,199
Technical Sentiment Signal: Sell
Current Market Cap: C$3.68M
Find detailed analytics on MBIO stock on TipRanks’ Stock Analysis page.